Mathieu Roche discusses the role of identity in digital advertising performance, emphasizing transparent data collection and ...

Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Former club captain Barry Roche leaves Morecambe after 17 years at the Shrimps that spanned both playing and coaching roles.

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

With fewer than 200 trained dermatologists serving Malaysia's 33 million people[1]-just one specialist for every 165,000 ...